ArticleMedical oncology (Northwood, London, England)2025
Investigating the antiproliferative mechanisms of NaHS, a hydrogen sulfide donor, in the SH-SY5Y cell line.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Apigenin as a Multitarget Anticancer Agent: Coordinated Inhibition of EGFR/MAPK and PI3K/Akt Signaling in Hematologic Malignancies.International journal of molecular sciences · 2026Article
- Astaxanthin promotes apoptosis by suppressing growth signaling pathways in HT-29 colorectal cancer cells.Medical oncology (Northwood, London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma, a childhood cancer, arises from neural crest cells within the sympathetic nervous system. This study investigated the anticancer effects of the exogenous hydrogen sulfide (H₂S) donor, sodium hydrogen sulfide (NaHS), on neuroblastoma cells, elucidating how it inhibits cell proliferation. The study was conducted using the SH-SY5Y cell line. The cells were exposed to various concentrations of NaHS (32, 16, 8, 4, and 2 mM) for 24 h. Cell viability was assessed using the XTT assay. ELISA was used to measure levels of the growth signal factors HER-2, EGFR, mTOR, ERK-1, and ERK-2, as well as the apoptosis marker caspase-3. In addition, apoptosis was evaluated using the Muse Annexin V & Dead Cell Assay Kit. NaHS significantly reduced cell proliferation, as demonstrated by the XTT assay (p < 0.001). NaHS treatment also decreased levels of HER-2, EGFR, ERK-1, and ERK-2 (p < 0.05 to p < 0.01), while mTOR levels remained unchanged (p > 0.05) and caspase-3 levels increased (p < 0.001). Flow cytometry confirmed that NaHS treatment significantly increased the proportion of apoptotic cells (p < 0.001). The antiproliferative effect of NaHS against neuroblastoma appears to be mediated through the suppression of certain growth signal factors and the induction of apoptosis. These findings suggest that exogenous hydrogen sulfide donors hold promise as a potential therapeutic strategy for neuroblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.